Hosolvon DM Elixir
Green, vanillin, peppermint and menthol flavoured liquid.
Each 5 ml contains:
Bromhexine Hydrochloride 4.0 mg
Actions and Pharmacology
Bromhexine is a mucolytic used in the treatment of respiratory disorders
associated with productive cough, where it changes the structure of
bronchial secretions leading to a reduction in the viscosity of sputum.
Dextromethorphan Hydrobromide is a cough suppressant used for the relief of
non-productive cough. It has a central action on the cough centre in the
medulla. It is also an antagonist of N-methyl-D-aspartate (NMDA) receptors.
Dextromethorphan has no classical analgesic properties and little sedative
Bromhexine is rapidly absorbed from the gastrointestinal tract and undergoes
extensive first-pass metabolism in the liver. It is widely distributed to
body tissues. About 85 to 90% of a dose is excreted in the urine mainly as
metabolites. Bromhexine is highly bound to plasma proteins and has a
terminal elimination half-life of up to about 12 hours. It crosses the
blood-brain barrier and small amounts cross the placenta.
Dextromethorphan Hydrobromide is rapidly absorbed from the gastrointestinal
tract. It is metabolized in the liver excreted in the urine as unchanged
dextromethorphan and demethylated metabolites including dextrorphan. It is
reported to act within half an hour of administration by mouth and to exert
an effect for up to 6 hours.
For short term symptomatic relief of cough associated with reduction in
This medication is contraindicated with patients with sensitivity to
bromhexine and dextromethorphan or other components of the formulation.
The presence of other medical problems may affect the use of this
medication. A doctor should be consulted before using this medicine if any
other medical problems exist, especially: peptic ulceration, asthma, chronic
bronchitis, productive cough, emphysema, diabetes, hepatic function
impairment and respiration depression.
Bromhexine should be used with care in patients with a history of asthma and
peptic ulceration. Clearance of bromhexine or its
metabolites may be reduced in patients with severe hepatic or renal
Dextromethorphan should not be given to patients at risk of developing
respiratory failure and caution is needed in patients with a history of
asthma and should not be given during an acute attack.
This medicine may cause drowsiness and dizziness, less alert than normal or
to feel a false sense of well being. Patients should know how they react to
this medicine before they drive, use machines or doing anything that could
be dangerous if they are dizzy or are not alert and clearheaded. Children
should be supervised to avoid potential harm in bike riding or other
Not to be used in children less than 2 years of age. To be used with caution
and doctor's advice in children 2 to 6 years of age.
Use in pregnancy and lactation
It is advisable not to use this medication during the first trimester of
pregnancy. This medication also should be avoided during lactation.
Main Side/Adverse Effects
The side effects with this medication appear to be rare and may include:
gastrointestinal disturbance, transient rise in serum aminotransferase
values, headache, drowsiness, dizziness, sweating, skin rashes and
occasionally produced cough or bronchospasm in susceptible subjects,
confusion, constipation, nausea or vomiting and stomach pain.
Concurrent use of this medication with combination products containing any
of the following medications, may interact with dextromethorphan: central
nervous system (CNS) depressants, monoamine oxidase (MAO) inhibitors
phenelzine, procarbazine, selegiline and tranylcypromine; other enzyme
inhibitors like amiodarone or fluoxetine or quinidine; and
Symptoms of overdose:
Ataxia, blurred vision, coma, confusion, drowsiness or dizziness,
respiratory depression, severe nausea or vomiting, severe unusual excitement
nervousness, restlessness or irritability and urinary retention.
Treatment for overdose:
Treatment is symptomatic and is directed toward the affected body system.
Gastric lavage, assisted respiration, vital sign monitoring
and intravenous naloxone are some of the possible prescribed treatment.
Dosage and Administration
Adult and children over 12 years: 10 ml (2 teaspoons), 3 times daily.
Children 6 to 12 years: 5 ml (1 teaspoon), 3 times daily.
Children 2 to 6 years: A doctor's direction is recommended as young children
have a greater chance of experiencing serious adverse effects.
Children below 2 years: Not recommended.
Patients are advised to use a calibrated measuring device as 5 ml is a rough
approximation of one teaspoon and different teaspoons differ in their
Storage: Store below 25°C.
Protect from light.
Presentation/Packing: Plastic bottle of 120 ml.